CN109476611A - 一种卤代化合物及其轴手性异构体 - Google Patents

一种卤代化合物及其轴手性异构体 Download PDF

Info

Publication number
CN109476611A
CN109476611A CN201780037722.6A CN201780037722A CN109476611A CN 109476611 A CN109476611 A CN 109476611A CN 201780037722 A CN201780037722 A CN 201780037722A CN 109476611 A CN109476611 A CN 109476611A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780037722.6A
Other languages
English (en)
Other versions
CN109476611B (zh
Inventor
王建非
张杨
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109476611A publication Critical patent/CN109476611A/zh
Application granted granted Critical
Publication of CN109476611B publication Critical patent/CN109476611B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种卤代化合物及其轴手性异构体，及其在制备与治疗尿酸水平异常密切相关病症的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201780037722.6A 2016-06-17 2017-06-13 一种卤代化合物及其轴手性异构体 Active CN109476611B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201610440804 2016-06-17
CN2016104408042 2016-06-17
CN2016105179799 2016-07-04
CN201610517979 2016-07-04
CN201610693528 2016-08-18
CN2016106935280 2016-08-18
PCT/CN2017/088031 WO2017215589A1 (zh) 2016-06-17 2017-06-13 一种卤代化合物及其轴手性异构体

Publications (2)

Publication Number Publication Date
CN109476611A true CN109476611A (zh) 2019-03-15
CN109476611B CN109476611B (zh) 2022-08-23

Family

ID=60663048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780037722.6A Active CN109476611B (zh) 2016-06-17 2017-06-13 一种卤代化合物及其轴手性异构体

Country Status (8)

Country Link
US (1) US10633351B2 (zh)
EP (1) EP3473617B1 (zh)
JP (1) JP7050009B2 (zh)
KR (1) KR102329486B1 (zh)
CN (1) CN109476611B (zh)
DK (1) DK3473617T3 (zh)
ES (1) ES2931470T3 (zh)
WO (1) WO2017215589A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019114838A1 (zh) * 2017-12-15 2019-06-20 南京明德新药研发股份有限公司 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
WO2021249468A1 (zh) * 2020-06-11 2021-12-16 南京明德新药研发有限公司 一种氯代化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法
CN102186832A (zh) * 2008-09-04 2011-09-14 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
CN105399694A (zh) * 2015-12-11 2016-03-16 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52632B (en) * 2004-08-25 2013-06-28 Ardea Biosciences Inc. S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
CN103524440B (zh) 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN105294585B (zh) * 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法
CN102186832A (zh) * 2008-09-04 2011-09-14 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN105399694A (zh) * 2015-12-11 2016-03-16 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3473617A4 (en) 2020-01-22
EP3473617A1 (en) 2019-04-24
KR102329486B1 (ko) 2021-11-22
US10633351B2 (en) 2020-04-28
JP2019518060A (ja) 2019-06-27
JP7050009B2 (ja) 2022-04-07
ES2931470T3 (es) 2022-12-29
DK3473617T3 (da) 2022-11-28
WO2017215589A1 (zh) 2017-12-21
CN109476611B (zh) 2022-08-23
EP3473617B1 (en) 2022-09-07
US20190337904A1 (en) 2019-11-07
KR20190017890A (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
CN105399694B (zh) 药物Lesinurad轴手性对映体
JP6725530B2 (ja) 軸方向キラル異性体及びその製造方法と製薬用途
US10752653B2 (en) Oxysterols and methods of use thereof
EP3348557B1 (en) Imidazo[1,2a]pyridines for treating or preventing hyperuricemia or gout
CN109476611A (zh) 一种卤代化合物及其轴手性异构体
JP4814789B2 (ja) ６−ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
CN109790155A (zh) 噻吩化合物及其合成方法和其在医药上的应用
EP3243823B1 (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
CN108553456B (zh) 苯甲酸及其衍生物的用途
WO2008000142A1 (fr) Agoniste du transporteur de la dopamine et ses utilisations
Lu et al. Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid derivatives as novel P2Y14R antagonists with potential high efficiency against acute gouty arthritis
KR102660247B1 (ko) 4-(나프탈렌-1-일)-4h-1, 2, 4-트리아졸계 화합물의 결정 형태, 염 형태 및 이의 제조방법
CN110590779B (zh) 3，10二对氯苯基6，12二氮杂四高立方烷类化合物及其合成方法、应用和药物组合物
WO2021204192A1 (zh) 化合物作为Sirt1受体激动剂的应用
CN112457291B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
CN111592552A (zh) 一种吡喃酮类化合物及其用途
CN104586863A (zh) 双没食子酸酯衍生物在制备治疗高尿酸血症药物中的用途
CN110240583A (zh) 一种苯并吡喃类化合物、及其制备方法和药物组合物与用途
US20210338703A1 (en) Process for the isolation of novel glycosides from pterocarpus marsupium and their therapeutic effects

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: MEDSHINE DISCOVERY Inc.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230424

Address after: 222047 Jiangning Industrial Park, Lianyungang Economic and Technological Development Zone, Jiangsu Province

Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.